間葉系幹細胞市場、2028年-世界の産業規模、動向、機会、予測、2018-2028年製品・サービス別、ワークフロー別、製品タイプ別、単離元別、適応症別、用途別、地域別、競合

間葉系幹細胞の世界市場規模は2022年に27億1,000万米ドルとなり、2028年までのCAGRは12.37%で、予測期間中に目覚ましい成長を遂げると予測されています。

世界の間葉系幹細胞（MSCs）市場は、再生医療の進歩、治療可能性への認識の高まり、臨床試験の増加により、近年著しい成長を遂げています。間葉系幹細胞は、多能性間質細胞としても知られ、様々な細胞型に分化するユニークな能力を持つことから大きな注目を集めており、様々な病状を治療するための貴重な資源となっています。

間葉系幹細胞は、骨髄、脂肪組織、臍帯血、歯髄など様々な組織に存在する成体幹細胞の一種です。間葉系幹細胞は骨、軟骨、脂肪組織、その他の細胞に分化する能力を持ち、再生医療における万能のツールとなっています。間葉系幹細胞は、その免疫調節特性、低免疫原性、抗炎症作用で知られ、幅広い疾患の治療可能性に寄与しています。

間葉系幹細胞は再生医療の最前線にあります。間葉系幹細胞は、組織の修復と再生において計り知れない可能性を秘めており、変形性関節症、心血管疾患、脊髄損傷などの治療において非常に貴重な存在となっています。様々な用途にMSCを使用する臨床試験の増加は、市場成長の重要な促進要因です。研究者たちは、COVID-19、糖尿病、神経変性疾患、自己免疫疾患の治療におけるMSCの可能性を探っています。MSCは特定の治療領域に限定されるものではないです。その適応性と安全性プロファイルは、整形外科、皮膚科、腫瘍学など多様な分野での探求につながっています。世界の高齢化は、再生療法に対する需要を高めています。高齢化が進むにつれて、変形性関節症やアルツハイマー病といった加齢に関連した疾患の有病率が増加し、MSCを用いた治療法の需要にさらに拍車をかけています。官民双方からの投資の増加は、MSC市場における研究開発努力を加速させています。このような資金は、製造能力の拡大や臨床試験をサポートしています。

市場促進要因

慢性疾患の有病率の上昇が間葉系幹細胞の世界市場を牽引

世界のヘルスケアの状況は、主に慢性疾患の有病率の上昇により、大きな変革期を迎えています。糖尿病、心血管疾患、関節炎、神経変性疾患などの慢性疾患は世界の健康課題となっており、数百万人の生命に影響を与え、ヘルスケアシステムを圧迫しています。この危機的状況に対し、研究者やヘルスケア専門家は革新的な治療法に目を向けており、その有望なアプローチのひとつが間葉系幹細胞（MSC）の利用です。間葉系幹細胞の世界市場は、慢性疾患と闘うための再生医療や細胞を用いた治療に対する需要の高まりに牽引され、著しい成長を遂げています。

バイオテクノロジーへの投資の増加が世界のメンズヘルスサプリメント市場を牽引

バイオテクノロジーの分野は急速に進歩しており、ヘルスケアにおける画期的な発見と革新につながっています。最もエキサイティングな進展のひとつは、間葉系幹細胞（MSCs）への注目の高まりと、再生医療や細胞治療への応用の可能性です。世界の間葉系幹細胞市場は著しい成長を遂げているが、その主な要因はバイオテクノロジー研究開発への投資が急増していることです。

バイオテクノロジー分野は、特に細胞生物学と遺伝子工学の分野で大きな進歩を遂げています。こうした画期的な進歩により、研究者はMSCの潜在能力を治療目的で最大限に活用できるようになっています。MSC生物学への理解が深まり、スケーラブルな製造プロセスが開発されたことで、MSCの臨床応用が加速しています。バイオテクノロジーの研究開発への投資は、近年大幅に増加しています。官民両部門が、MSCの治療応用を模索する研究プロジェクトを支援するために、多額の資金を割り当てています。このような資金援助は、臨床試験を進め、有望な治療法を市場承認に近づけるのに役立っています。

意識の高まりと患者の需要が世界のメンズヘルスサプリメント市場を牽引

世界の間葉系幹細胞（MSCs）市場は著しい急成長を遂げているが、この現象は、MSCsの潜在的な治療用途に対する意識の高まりと、革新的な再生医療ソリューションを求める患者からの需要の高まりに起因しています。MSCの治療可能性に関する意識は、ヘルスケア専門家と一般大衆の両者の間で着実に高まっています。臨床研究や成功例から、変形性関節症、自己免疫疾患、心血管系障害といった疾患の治療におけるMSCを用いた療法の有効性が浮き彫りになってきました。このような意識の高まりにより、MSCを用いた治療を求める患者が増加しています。MSCを用いた臨床試験の数は増加の一途をたどっており、その適用範囲は整形外科から心臓病学まで多岐にわたる。このような臨床研究の急増は、MSCを用いた治療の可能性を裏付けるだけでなく、研究機関と製薬企業とのコラボレーションを促進するものでもあります。MSCはもはや損傷組織の再生に限定されるものではなく、その免疫調節特性についてますます研究が進んでいます。炎症性疾患や自己免疫疾患の治療の可能性が研究され、市場の可能性を広げています。

主な市場課題

規制上の課題

世界のMSCs市場における最大の課題の一つは、複雑で進化する規制状況です。規制機関は国によって異なるため、企業がMSCベースの治療法の承認プロセスを進めるのは困難です。適正製造基準（GMP）を含む様々な規制への準拠を達成することは、コストと時間のかかる努力です。これらの規制を調和させ、世界的に認知された枠組みを育成することは、市場の成長を加速させるために不可欠です。

調達と品質管理

高品質なMSCの確実な調達は、業界における重要な関心事です。MSCの一貫性、純度、力価を確保することは、治療の成功に不可欠です。一貫性のあるドナー組織を入手し、細胞の増殖と保存中に細胞の品質を維持するためには、課題が生じる。細胞培養技術の革新と標準化されたプロトコールは、こうした懸念に対処するのに役立ちます。

拡張性

MSCを用いた治療に対する需要が高まるにつれて、拡張性が極めて重要な問題となります。細胞の品質を維持しながら、拡大する市場需要に応えるためにMSC生産を拡大することは、大きな課題です。供給不足を回避し、これらの療法の総コストを削減するためには、費用対効果が高く、拡張性のある製造プロセスを開発することが不可欠です。

競合と知的財産

MSCs市場は競争が激しく、数多くの企業や研究機関がMSCを用いた治療法を積極的に追求しています。知的財産の争奪戦や特許戦争は珍しくなく、業界内の革新や協力の妨げとなっています。知的財産を共有するための明確なガイドラインや仕組みを確立することは、こうした課題を克服するのに役立ちます。

臨床試験の複雑さ

MSCを用いた治療法の臨床試験の実施には、独特の課題があります。大規模で多様な患者集団、長期の追跡調査、標準化された転帰測定の必要性は、論理的にも財政的にも厳しいものです。産業界の利害関係者、学術界、規制当局が協力することで、臨床試験プロセスを合理化し、データの共有を促進することができます。

倫理的懸念

MSCの倫理的使用は、依然として論争の的となっている。MSCの供給源は骨髄や脂肪組織に由来することが多く、ドナーの同意、組織の調達、治療法への公平なアクセスに関する問題を提起しています。研究と臨床応用における透明性、インフォームド・コンセント、倫理的実践を確保することは、社会からの信頼を維持するために最も重要です。

コストと償還

MSCを用いた治療法は、生産、規制、品質管理が複雑なため、高額になることが多いです。ヘルスケアシステムや保険プロバイダーからの償還を確保することは困難であり、このような革新的な治療法への患者のアクセスを制限する可能性があります。価格設定と償還の問題に対処するためには、利害関係者間の協力が不可欠です。

市場の断片化

世界のMSCs市場は断片化されており、大手製薬企業とともに多数の中小企業（SME）が活動しています。業界内の統合は、リソースの有効活用、調査努力の合理化、中小企業の資本アクセスの改善につながる可能性があります。

主な市場動向

技術の進歩

幹細胞研究の目覚ましい進展と最先端技術の開発により、再生医療分野は近年大きく変貌を遂げています。様々な種類の幹細胞の中でも、間葉系幹細胞（MSC）は様々な病態を治療する可能性があるとして大きな注目を集めています。世界の間葉系幹細胞市場は、科学の飛躍的進歩と技術の進歩の融合に後押しされ、急速な成長を遂げています。

間葉系幹細胞の培養は、先進的なバイオリアクター、3Dスキャフォールド、マイクロ流体システムの利用により、より効率的で再現性の高いものとなっています。このような技術により、研究者たちは治療目的の高品質なMSCを大量に生産できるようになっています。CRISPR-Cas9のような遺伝子組み換え技術によって、科学者たちはMSCsの治療可能性を高めることができるようになっています。これには、再生特性を高めたり、免疫反応を調節したりする特定のタンパク質や因子を発現するように、MSCを調整することも含まれます。バイオマテリアルやドラッグデリバリーシステムの革新は、MSCを体内の特定部位に標的を定めて制御しながら送達することを可能にしました。これにより、MSCを用いた療法の有効性と安全性が向上しています。自動化とロボット工学は、MSCベースの製品の製造工程を合理化し、コストを削減し、一貫した製品の品質を保証しています。これは、MSC療法の拡張性に不可欠です。磁気共鳴画像法（MRI）や生物発光イメージングなどの高度なイメージング技術により、研究者は移植されたMSCの体内での運命を追跡し、治療戦略を最適化し、患者の転帰を改善することができます。

セグメント別インサイト

ワークフローインサイト

ワークフローのカテゴリーに基づくと、バイオアベイラビリティ＆生物学的同等性試験セグメントが、2022年の間葉系幹細胞の世界市場で支配的なプレーヤーとして浮上しました。培養と凍結保存は、間葉系幹細胞の維持と増殖に不可欠です。MSCは通常、骨髄、脂肪組織、臍帯血など様々な供給源から単離されます。いったん単離されると、治療応用に十分な数まで増殖させるために培養する必要があります。凍結保存は、治療特性を大きく損なうことなく、これらの細胞を長期保存することを可能にします。このプロセスにより、研究および臨床使用のためのMSCの安定供給が保証されます。培養と凍結保存の両分野は、再生医療や細胞ベースの治療法の分野における研究開発の取り組みと密接に結びついています。科学者や製薬会社は、MSCの潜在的な治療用途を理解するために広範な調査を行っており、これには培養や凍結保存でこれらの細胞を大量にストックしておくことがしばしば含まれます。多くの組織や研究機関が、将来の研究や臨床応用のために、MSCを含む細胞バンクを維持しています。これらの細胞バンクは、細胞の長期的な生存性を確保するために、強固な培養・凍結保存プロトコルを必要とします。このようなインフラは、様々な用途にMSCをスケーラビリティに利用するために不可欠です。MSCは、整形外科疾患、自己免疫疾患、組織再生など、様々な病状の治療において有望視されています。臨床試験や治療への応用は、多くの場合、凍結保存法を用いて保存・輸送される高品質のMSCの入手可能性に依存しています。

タイプ別洞察

同種移植セグメントは予測期間中に急成長すると予測されています。同種MSCは健康なドナーに由来し、管理された環境で大量に増殖させることができます。このため、臨床応用や研究における需要の高まりに対応するのに十分な量を容易に入手することができます。同種MSCは、厳格な品質管理のもとで生産されるため、細胞の特性、効力、安全性において一貫性が確保されます。このことは、再生医療や細胞を用いた治療への応用にとって極めて重要です。患者自身の組織から得られる自家MSCは、患者の年齢や健康状態により、品質や効力にばらつきが生じる可能性があります。一方、同種MSCは標準化されているため、ばらつきを抑えることができます。

地域別の洞察

2022年の間葉系幹細胞の世界市場では、北米が金額ベースで最大の市場シェアを占め、圧倒的な存在感を示しました。北米、特に米国は、ヘルスケアとバイオテクノロジー部門が発達しています。この地域には数多くの研究機関、大学、製薬会社があり、幹細胞の研究開発に多額の投資を行っています。このような広範な研究開発インフラが、幹細胞治療や製品の進歩に寄与しています。北米の規制環境は、幹細胞研究や臨床試験を比較的支持しています。米国の食品医薬品局（FDA）のような組織は、MSCを用いた治療法の開発と使用に関する明確なガイドラインを定めており、これが投資家や研究者の信頼につながっています。北米は、MSC研究を含む再生医療分野に大きな投資を集めています。民間および公的資金源、ベンチャーキャピタル、助成金は、この地域における研究開発活動、臨床試験、商業化の取り組みを支援する上で重要な役割を果たしています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 間葉系幹細胞の世界市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品・サービス別（製品（細胞・細胞株、キット・培地・試薬、その他）、サービス）
  • ワークフロー別（細胞調達・単離、培養・凍結保存、分化、特性解析）
  • タイプ別（自家、同種）
  • 分離源別（骨髄、臍帯血、末梢血、卵管、胎児肝、肺、脂肪組織）
  • 適応症別（骨・軟骨修復、心血管疾患、炎症・免疫疾患、肝疾患、がん、GvHD、その他）
  • 用途別（疾患モデリング、医薬品開発・発見、幹細胞バンク、組織工学、毒性学研究、その他）
  • 地域別
  • 企業別（2022年）
• 市場マップ

第6章 北米間葉系幹細胞市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品・サービス別
  • ワークフロー別
  • タイプ別
  • 分離源別
  • 適応症別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州間葉系幹細胞市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品・サービス別
  • ワークフロー別
  • タイプ別
  • 分離源別
  • 適応症別
  • 用途別
• 欧州国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋間葉系幹細胞市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品・サービス別
  • ワークフロー別
  • タイプ別
  • 分離源別
  • 適応症別
  • 用途別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米間葉系幹細胞市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品・サービス別
  • ワークフロー別
  • タイプ別
  • 分離源別
  • 適応症別
  • 用途別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカ間葉系幹細胞市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品・サービス別
  • ワークフロー別
  • タイプ別
  • 分離源別
  • 適応症別
  • 用途別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品開発
• 最近の動向

第13章 間葉系幹細胞の世界市場SWOT分析

第14章 競合情勢

• Business Overview
• Age Group Offerings
• Recent Developments
• Key Personnel
• SWOT Analysis
  • Thermo Fisher Scientific, Inc
  • Cell Applications, Inc
  • Axol Biosciences Ltd
  • Cytori Therapeutics Inc
  • STEMCELL Technologies
  • Cyagen Biosciences
  • Celprogen Inc
  • BrainStorm Cell Limited
  • Stemedica Cell Technologies Inc
  • Merck KGaA（MilliporeSigma）
  • PromoCell GmbH

第15章 戦略的提言

第16章 調査会社・免責事項

Global Mesenchymal Stem Cells Market has valued at USD 2.71 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 12.37% through 2028. The global mesenchymal stem cells (MSCs) market has been experiencing remarkable growth in recent years, thanks to advancements in regenerative medicine, increasing awareness of their therapeutic potential, and a rising number of clinical trials. Mesenchymal stem cells, also known as multipotent stromal cells, have garnered significant attention for their unique ability to differentiate into various cell types, making them a valuable resource for treating a wide range of medical conditions.

Mesenchymal stem cells are a type of adult stem cell found in various tissues, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. They have the ability to differentiate into bone, cartilage, adipose tissue, and other cell types, making them a versatile tool in regenerative medicine. These cells are known for their immunomodulatory properties, low immunogenicity, and anti-inflammatory effects, which contribute to their therapeutic potential in treating a wide range of diseases.

Mesenchymal stem cells have been at the forefront of regenerative medicine. They hold immense potential in tissue repair and regeneration, making them invaluable for treating conditions such as osteoarthritis, cardiovascular diseases, and spinal cord injuries. The rise in clinical trials using MSCs for various applications is a significant driver of market growth. Researchers are exploring their potential in treating COVID-19, diabetes, neurodegenerative disorders, and autoimmune diseases. MSCs are not limited to a specific therapeutic area. Their adaptability and safety profile have led to exploration in diverse fields, including orthopedics, dermatology, and oncology. The global aging population has contributed to the demand for regenerative therapies. As people age, the prevalence of age-related diseases such as osteoarthritis and Alzheimer's disease has increased, further fueling the demand for MSC-based treatments. Increasing investments from both public and private sectors are accelerating research and development efforts in the MSC market. This funding supports the expansion of manufacturing capabilities and clinical trials.

Key Market Drivers

Rising Prevalence of Chronic Diseases is Driving the Global Mesenchymal Stem Cells Market

The global healthcare landscape is undergoing a significant transformation, primarily due to the rising prevalence of chronic diseases. Chronic diseases, such as diabetes, cardiovascular diseases, arthritis, and neurodegenerative disorders, have become a global health challenge, impacting millions of lives and straining healthcare systems. In response to this growing crisis, researchers and healthcare professionals are turning to innovative therapies, and one promising approach involves the use of mesenchymal stem cells (MSCs). The global mesenchymal stem cells market is witnessing remarkable growth, driven by the increasing demand for regenerative medicine and cell-based therapies to combat chronic diseases.

Chronic diseases are characterized by their long duration and slow progression, making them a significant burden on healthcare systems worldwide. The World Health Organization (WHO) estimates that chronic diseases are responsible for approximately 71% of all global deaths. These conditions not only impact the quality of life for individuals but also result in substantial economic costs due to increased healthcare expenditures and lost productivity.

As the global population continues to age, the risk of developing chronic diseases, such as Alzheimer's disease, Parkinson's disease, and osteoarthritis, increases significantly. Modern lifestyles often involve prolonged periods of inactivity, leading to an increased risk of obesity, type 2 diabetes, and cardiovascular diseases. Poor dietary choices, including excessive consumption of processed foods high in sugar and unhealthy fats, contribute to the development of chronic conditions like diabetes and hypertension. Environmental factors, such as air pollution and exposure to harmful chemicals, can contribute to the development of respiratory diseases and cancers.

Mesenchymal stem cells hold great promise as a therapeutic option for chronic diseases due to their regenerative and immunomodulatory properties. They can be used in several ways to address these conditions. MSCs can differentiate into various cell types, making them valuable in regenerating damaged tissues and organs. They have shown promise in treating conditions like osteoarthritis, where they can stimulate cartilage repair. MSCs possess immunomodulatory properties that can help regulate the immune system's response. This is particularly relevant in autoimmune diseases, where an overactive immune system attacks healthy tissues. MSCs can dampen this response and reduce inflammation. MSCs can be used in tissue engineering to create artificial organs or tissues for transplantation. This has the potential to revolutionize the treatment of diseases like diabetes, where pancreatic tissue can be engineered to produce insulin.

Increasing Investment in Biotechnology is Driving the Global Men's Health Supplements Market

The field of biotechnology has been rapidly advancing, leading to groundbreaking discoveries and innovations in healthcare. One of the most exciting developments is the increased focus on mesenchymal stem cells (MSCs) and their potential applications in regenerative medicine and cell therapy. The global mesenchymal stem cells market is experiencing significant growth, largely attributed to the escalating investments in biotechnology research and development.

The biotechnology sector has witnessed substantial advancements, particularly in the fields of cell biology and genetic engineering. These breakthroughs have enabled researchers to harness the full potential of MSCs for therapeutic purposes. Improved understanding of MSC biology and the development of scalable manufacturing processes have accelerated their clinical translation. Investment in biotechnology research and development has seen a significant uptick in recent years. Both public and private sectors have allocated substantial funds to support research projects exploring the therapeutic applications of MSCs. This funding has been instrumental in advancing clinical trials and bringing promising therapies closer to market approval.

Rising Awareness and Patient Demand is Driving the Global Men's Health Supplements Market

The global mesenchymal stem cells (MSCs) market is experiencing a significant surge in growth, and this phenomenon can be attributed to the rising awareness of the potential therapeutic applications of MSCs and the increasing demand from patients seeking innovative regenerative medicine solutions. Awareness about the therapeutic potential of MSCs has been steadily growing among both healthcare professionals and the general public. Clinical studies and successful cases have highlighted the efficacy of MSC-based therapies in treating conditions like osteoarthritis, autoimmune diseases, and cardiovascular disorders. This heightened awareness has prompted more patients to seek MSC-based treatments. The number of clinical trials involving MSCs has been on the rise, covering a wide range of applications, from orthopedics to cardiology. This surge in clinical research not only validates the potential of MSC-based treatments but also fosters collaborations between research institutions and the pharmaceutical industry. MSCs are no longer limited to regenerating damaged tissues but are increasingly being explored for their immunomodulatory properties. They are being investigated for their potential in treating inflammatory and autoimmune diseases, expanding their market potential.

Key Market Challenges

Regulatory Challenges

One of the foremost challenges in the global MSCs market is the complex and evolving regulatory landscape. Regulatory bodies vary from country to country, making it difficult for companies to navigate the approval process for MSC-based therapies. Achieving compliance with various regulations, including Good Manufacturing Practices (GMP), is a costly and time-consuming endeavor. Harmonizing these regulations and fostering a globally recognized framework is essential to accelerate market growth.

Sourcing and Quality Control

The reliable sourcing of high-quality MSCs is a significant concern in the industry. Ensuring the consistency, purity, and potency of MSCs is critical for therapeutic success. Challenges arise in obtaining consistent donor tissues and maintaining cell quality during expansion and storage. Innovations in cell culture techniques and standardized protocols can help address these concerns.

Scalability

As the demand for MSC-based therapies increases, scalability becomes a crucial issue. Expanding MSC production to meet the growing market demand while maintaining cell quality is a substantial challenge. Developing cost-effective and scalable manufacturing processes is essential to avoid supply shortages and reduce the overall cost of these therapies.

Competition and Intellectual Property

The MSCs market is highly competitive, with numerous companies and research institutions actively pursuing MSC-based therapies. Intellectual property disputes and patent wars are not uncommon, hindering innovation and collaboration within the industry. Establishing clear guidelines and mechanisms for intellectual property sharing can help overcome these challenges.

Clinical Trial Complexities

Conducting clinical trials for MSC-based therapies presents unique challenges. The need for large, diverse patient populations, long-term follow-ups, and standardized outcome measures can be logistically and financially demanding. Collaboration between industry stakeholders, academia, and regulatory bodies can streamline the clinical trial process and facilitate data sharing.

Ethical Concerns

The ethical use of MSCs remains a contentious issue. The source of MSCs, often derived from bone marrow or adipose tissue, raises questions about donor consent, tissue sourcing, and equitable access to therapies. Ensuring transparency, informed consent, and ethical practices in research and clinical applications is paramount to maintaining public trust.

Cost and Reimbursement

MSC-based therapies are often expensive due to the complexities of production, regulation, and quality control. Securing reimbursement from healthcare systems and insurance providers can be challenging, limiting patient access to these innovative treatments. Collaborative efforts between stakeholders are essential to address pricing and reimbursement issues.

Market Fragmentation

The global MSCs market is fragmented, with numerous small and medium-sized enterprises (SMEs) operating alongside large pharmaceutical companies. Consolidation within the industry can lead to better resource utilization, streamlined research efforts, and improved access to capital for smaller players.

Key Market Trends

Technological Advancements

The field of regenerative medicine has been revolutionized in recent years, thanks to the remarkable progress in stem cell research and the development of cutting-edge technologies. Among the various types of stem cells, mesenchymal stem cells (MSCs) have garnered significant attention for their potential to treat a wide range of medical conditions. The global mesenchymal stem cells market is experiencing rapid growth, fueled by the convergence of scientific breakthroughs and technological advancements.

The culturing of MSCs has become more efficient and reproducible through the use of advanced bioreactors, 3D scaffolds, and microfluidic systems. These technologies have enabled researchers to produce large quantities of high-quality MSCs for therapeutic purposes. Genetic modification techniques, such as CRISPR-Cas9, have allowed scientists to enhance the therapeutic potential of MSCs. This includes tailoring MSCs to express specific proteins or factors that can boost their regenerative properties or modulate immune responses. Innovations in biomaterials and drug delivery systems have enabled the targeted and controlled delivery of MSCs to specific sites within the body. This has improved the efficacy and safety of MSC-based therapies. Automation and robotics are streamlining the manufacturing process of MSC-based products, reducing costs, and ensuring consistent product quality. This is essential for the scalability of MSC therapies. Advanced imaging techniques, such as magnetic resonance imaging (MRI) and bioluminescent imaging, allow researchers to track the fate of transplanted MSCs within the body, optimizing treatment strategies and improving patient outcomes.

Segmental Insights

Workflow Insights

Based on the category of Workflow, the bioavailability & bioequivalence studies segment emerged as the dominant player in the global market for Mesenchymal Stem Cells in 2022. Culture and cryopreservation are critical for the maintenance and expansion of MSCs. MSCs are typically isolated from various sources, such as bone marrow, adipose tissue, or umbilical cord blood. Once isolated, they need to be cultured to grow in sufficient numbers for therapeutic applications. Cryopreservation allows for long-term storage of these cells without significant loss of their therapeutic properties. This process ensures a stable supply of MSCs for research and clinical use. The culture and cryopreservation segments are closely tied to research and development efforts in the field of regenerative medicine and cell-based therapies. Scientists and pharmaceutical companies conduct extensive research to understand the potential therapeutic applications of MSCs, and this often involves maintaining large stocks of these cells in culture and cryopreservation. Many organizations and institutions maintain cell banks, which include MSCs, for future research and clinical applications. These cell banks require robust culture and cryopreservation protocols to ensure the long-term viability of the cells. This infrastructure is essential for the scalability and availability of MSCs for various applications. MSCs have shown promise in treating various medical conditions, including orthopedic disorders, autoimmune diseases, and tissue regeneration. Clinical trials and therapeutic applications often rely on the availability of high-quality MSCs, which are stored and transported using cryopreservation methods.

Type Insights

The Allogeneic segment is projected to experience rapid growth during the forecast period. Allogeneic MSCs are derived from healthy donors and can be expanded in large quantities in a controlled environment. This makes them more readily available in sufficient quantities to meet the growing demand in clinical applications and research. Allogeneic MSCs can be produced under strict quality control measures, ensuring consistency in cell characteristics, potency, and safety. This is critical for applications in regenerative medicine and cell-based therapies. Autologous MSCs, which are obtained from a patient's own tissue, may exhibit variability in quality and potency due to the patient's age and health condition. Allogeneic MSCs, on the other hand, can be standardized, reducing variability.

Regional Insights

North America emerged as the dominant player in the global Mesenchymal Stem Cells market in 2022, holding the largest market share in terms of value. North America, particularly the United States, has a well-developed and advanced healthcare and biotechnology sector. The region is home to numerous research institutions, universities, and pharmaceutical companies that invest heavily in stem cell research and development. This extensive R&D infrastructure has contributed to advancements in MSC therapies and products. The regulatory environment in North America has been relatively supportive of stem cell research and clinical trials. Organizations like the Food and Drug Administration (FDA) in the United States have established clear guidelines for the development and use of MSC-based therapies, which has given confidence to investors and researchers. North America has attracted significant investments in the field of regenerative medicine, including MSC research. Private and public funding sources, venture capital, and grants have played a crucial role in supporting research and development activities, clinical trials, and commercialization efforts in the region.

Key Market Players

• Thermo Fisher Scientific, Inc

• Cell Applications, Inc

• Axol Biosciences Ltd

• Cytori Therapeutics Inc

• STEMCELL Technologies

• Cyagen Biosciences

• Celprogen Inc

• BrainStorm Cell Limited

• Stemedica Cell Technologies Inc

• Merck KGaA (MilliporeSigma)

• PromoCell GmbH

Report Scope:

In this report, the Global Mesenchymal Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mesenchymal Stem Cells Market, By Product & Services:

Product

Services

Mesenchymal Stem Cells Market, By Workflow:

Cell Sourcing & Isolation

Culture & Cryopreservation

Differentiation

Characterization

Mesenchymal Stem Cells Market, By Type:

• Autologous
• Allogeneic

Mesenchymal Stem Cells Market, By Source of Isolation:

• Bone Marrow
• Cord Blood
• Peripheral Blood
• Fallopian Tube
• Fetal Liver
• Lung
• Adipose Tissues

Mesenchymal Stem Cells Market, By Indication:

• Bone And Cartilage Repair
• Cardiovascular Disease
• Inflammatory And Immunological Diseases
• Liver Diseases
• Cancer
• GvHD
• Others

Mesenchymal Stem Cells Market, By Application:

• Disease Modelling
• Drug Development & Discovery
• Stem Cell Banking
• Tissue Engineering
• Toxicology Studies
• Others

Mesenchymal Stem Cells Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Mesenchymal Stem Cells Market.

Available Customizations:

• Global Mesenchymal Stem Cells market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Mesenchymal Stem Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Services (Products(Cells & Cell Lines, Kits, Media, & Reagents, Others), Services)
  • 5.2.2. By Workflow ( Cell Sourcing & Isolation, Culture & Cryopreservation, Differentiation, Characterization)
  • 5.2.3. By Type ( Autologous, Allogeneic)
  • 5.2.4. By Source of Isolation( Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung, Adipose Tissues)
  • 5.2.5. By Indication (Bone And Cartilage Repair, Cardiovascular Disease, Inflammatory And Immunological Diseases, Liver Diseases, Cancer, GvHD, Others)
  • 5.2.6. By Application ( Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2022)
• 5.3. Market Map

6. North America Mesenchymal Stem Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Services
  • 6.2.2. By Workflow
  • 6.2.3. By Type
  • 6.2.4. By Source of Isolation
  • 6.2.5. By Indication
  • 6.2.6. By Application
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Mesenchymal Stem Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Services
      • 6.3.1.2.2. By Workflow
      • 6.3.1.2.3. By Type
      • 6.3.1.2.4. By Source of Isolation
      • 6.3.1.2.5. By Indication
      • 6.3.1.2.6. By Application
  • 6.3.2. Canada Mesenchymal Stem Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Services
      • 6.3.2.2.2. By Workflow
      • 6.3.2.2.3. By Type
      • 6.3.2.2.4. By Source of Isolation
      • 6.3.2.2.5. By Indication
      • 6.3.2.2.6. By Application
  • 6.3.3. Mexico Mesenchymal Stem Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Services
      • 6.3.3.2.2. By Workflow
      • 6.3.3.2.3. By Type
      • 6.3.3.2.4. By Source of Isolation
      • 6.3.3.2.5. By Indication
      • 6.3.3.2.6. By Application

7. Europe Mesenchymal Stem Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Services
  • 7.2.2. By Workflow
  • 7.2.3. By Type
  • 7.2.4. By Source of Isolation
  • 7.2.5. By Indication
  • 7.2.6. By Application
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Mesenchymal Stem Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Services
      • 7.3.1.2.2. By Workflow
      • 7.3.1.2.3. By Type
      • 7.3.1.2.4. By Source of Isolation
      • 7.3.1.2.5. By Indication
      • 7.3.1.2.6. By Application
  • 7.3.2. United Kingdom Mesenchymal Stem Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Services
      • 7.3.2.2.2. By Workflow
      • 7.3.2.2.3. By Type
      • 7.3.2.2.4. By Source of Isolation
      • 7.3.2.2.5. By Indication
      • 7.3.2.2.6. By Application
  • 7.3.3. Italy Mesenchymal Stem Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product & Services
      • 7.3.3.2.2. By Workflow
      • 7.3.3.2.3. By Type
      • 7.3.3.2.4. By Source of Isolation
      • 7.3.3.2.5. By Indication
      • 7.3.3.2.6. By Application
  • 7.3.4. France Mesenchymal Stem Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Services
      • 7.3.4.2.2. By Workflow
      • 7.3.4.2.3. By Type
      • 7.3.4.2.4. By Source of Isolation
      • 7.3.4.2.5. By Indication
      • 7.3.4.2.6. By Application
  • 7.3.5. Spain Mesenchymal Stem Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Services
      • 7.3.5.2.2. By Workflow
      • 7.3.5.2.3. By Type
      • 7.3.5.2.4. By Source of Isolation
      • 7.3.5.2.5. By Indication
      • 7.3.5.2.6. By Application

8. Asia-Pacific Mesenchymal Stem Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Services
  • 8.2.2. By Workflow
  • 8.2.3. By Type
  • 8.2.4. By Source of Isolation
  • 8.2.5. By Indication
  • 8.2.6. By Application
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Mesenchymal Stem Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Services
      • 8.3.1.2.2. By Workflow
      • 8.3.1.2.3. By Type
      • 8.3.1.2.4. By Source of Isolation
      • 8.3.1.2.5. By Indication
      • 8.3.1.2.6. By Application
  • 8.3.2. India Mesenchymal Stem Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Services
      • 8.3.2.2.2. By Workflow
      • 8.3.2.2.3. By Type
      • 8.3.2.2.4. By Source of Isolation
      • 8.3.2.2.5. By Indication
      • 8.3.2.2.6. By Application
  • 8.3.3. Japan Mesenchymal Stem Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Services
      • 8.3.3.2.2. By Workflow
      • 8.3.3.2.3. By Type
      • 8.3.3.2.4. By Source of Isolation
      • 8.3.3.2.5. By Indication
      • 8.3.3.2.6. By Application
  • 8.3.4. South Korea Mesenchymal Stem Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Services
      • 8.3.4.2.2. By Workflow
      • 8.3.4.2.3. By Type
      • 8.3.4.2.4. By Source of Isolation
      • 8.3.4.2.5. By Indication
      • 8.3.4.2.6. By Application
  • 8.3.5. Australia Mesenchymal Stem Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Services
      • 8.3.5.2.2. By Workflow
      • 8.3.5.2.3. By Type
      • 8.3.5.2.4. By Source of Isolation
      • 8.3.5.2.5. By Indication
      • 8.3.5.2.6. By Application

9. South America Mesenchymal Stem Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Services
  • 9.2.2. By Workflow
  • 9.2.3. By Type
  • 9.2.4. By Source of Isolation
  • 9.2.5. By Indication
  • 9.2.6. By Application
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Mesenchymal Stem Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Services
      • 9.3.1.2.2. By Workflow
      • 9.3.1.2.3. By Type
      • 9.3.1.2.4. By Source of Isolation
      • 9.3.1.2.5. By Indication
      • 9.3.1.2.6. By Application
  • 9.3.2. Argentina Mesenchymal Stem Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Services
      • 9.3.2.2.2. By Workflow
      • 9.3.2.2.3. By Type
      • 9.3.2.2.4. By Source of Isolation
      • 9.3.2.2.5. By Indication
      • 9.3.2.2.6. By Application
  • 9.3.3. Colombia Mesenchymal Stem Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Services
      • 9.3.3.2.2. By Workflow
      • 9.3.3.2.3. By Type
      • 9.3.3.2.4. By Source of Isolation
      • 9.3.3.2.5. By Indication
      • 9.3.3.2.6. By Application

10. Middle East and Africa Mesenchymal Stem Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Services
  • 10.2.2. By Workflow
  • 10.2.3. By Type
  • 10.2.4. By Source of Isolation
  • 10.2.5. By Indication
  • 10.2.6. By Application
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Mesenchymal Stem Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Services
      • 10.3.1.2.2. By Workflow
      • 10.3.1.2.3. By Type
      • 10.3.1.2.4. By Source of Isolation
      • 10.3.1.2.5. By Indication
      • 10.3.1.2.6. By Application
  • 10.3.2. Saudi Arabia Mesenchymal Stem Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Services
      • 10.3.2.2.2. By Workflow
      • 10.3.2.2.3. By Type
      • 10.3.2.2.4. By Source of Isolation
      • 10.3.2.2.5. By Indication
      • 10.3.2.2.6. By Application
  • 10.3.3. UAE Mesenchymal Stem Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Services
      • 10.3.3.2.2. By Workflow
      • 10.3.3.2.3. By Type
      • 10.3.3.2.4. By Source of Isolation
      • 10.3.3.2.5. By Indication
      • 10.3.3.2.6. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Global Mesenchymal Stem Cells Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Age Group Offerings
• 14.3. Recent Developments
• 14.4. Key Personnel
• 14.5. SWOT Analysis
  • 14.5.1. Thermo Fisher Scientific, Inc
  • 14.5.2. Cell Applications, Inc
  • 14.5.3. Axol Biosciences Ltd
  • 14.5.4. Cytori Therapeutics Inc
  • 14.5.5. STEMCELL Technologies
  • 14.5.6. Cyagen Biosciences
  • 14.5.7. Celprogen Inc
  • 14.5.8. BrainStorm Cell Limited
  • 14.5.9. Stemedica Cell Technologies Inc
  • 14.5.10. Merck KGaA (MilliporeSigma)
  • 14.5.11. PromoCell GmbH

15. Strategic Recommendations

16. About Us & Disclaimer